Home > Boards > US Listed > Biotechs > Chembio Diagnostics (CEMI)

Repeating your post - this is interesting.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 346
Posts 46,246
Boards Moderated 26
Alias Born 09/20/01
160x600 placeholder
Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems GlobeNewswire Inc. - 1/14/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 9:24:22 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/18/2020 9:22:35 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2020 5:15:40 PM
Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors GlobeNewswire Inc. - 12/17/2020 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/4/2020 6:05:19 AM
Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submissi... GlobeNewswire Inc. - 12/2/2020 1:22:29 PM
Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil GlobeNewswire Inc. - 11/13/2020 4:40:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 5:11:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 4:17:04 PM
Chembio Diagnostics Reports Third Quarter 2020 Financial Results GlobeNewswire Inc. - 11/5/2020 4:05:00 PM
Chembio Diagnostics to Report Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire Inc. - 10/23/2020 8:00:10 AM
Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System GlobeNewswire Inc. - 10/15/2020 5:55:10 PM
Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System GlobeNewswire Inc. - 10/2/2020 7:26:09 AM
Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System GlobeNewswire Inc. - 9/8/2020 6:01:08 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2020 7:43:29 AM
Chembio Diagnostics Reports Second Quarter 2020 Financial Results GlobeNewswire Inc. - 8/6/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 7:19:40 AM
Chembio Diagnostics to Report Second Quarter 2020 Financial Results on August 6, 2020 GlobeNewswire Inc. - 7/23/2020 4:10:10 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/8/2020 10:00:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 9:43:40 AM
Chembio Diagnostics Announces Preliminary Estimates of Second Quarter 2020 Revenues GlobeNewswire Inc. - 7/6/2020 4:23:03 PM
Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen Sy... GlobeNewswire Inc. - 7/6/2020 4:11:10 PM
Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System GlobeNewswire Inc. - 7/6/2020 4:10:10 PM
Chembio to Report COVID-19 Product Development Plans and Preliminary Estimated Second Quarter 2020 Revenue Results GlobeNewswire Inc. - 7/1/2020 5:00:10 PM
XenaLives Member Level  Thursday, 10/08/20 10:20:33 AM
Re: keekee post# 323
Post # of 455 
Repeating your post - this is interesting.

PCR tests are unreliable, antibody tests tell more, but they are discoraged?

You seem to know a lot about this stock keekee, let's get a discussion on the fundamentals going.

Quote:
So, THE FDA DID NOT STOP Rapid DPP COVID-19 tests. The FDA merely revoked EAuth. Now read what I will post below....the FDA three days go just out saying Healthcare Providers should continue using these tesk systems, but just be aware of its limitations. Read below: CAUTION...I AM LOADED HUGE!

"The FDA is not aware of an antibody test that has been validated for diagnosis of SARS-CoV-2 infection. While the FDA remains open to receiving submissions for these tests for such uses, based on the underlying scientific principles of antibody tests, the FDA does not expect that an antibody test can be shown to definitively diagnose or exclude SARS-CoV-2 infection.

Recommendations
The FDA recommends health care providers:

Continue to use serological (antibody) tests, as appropriate, and be aware of their limitations.
Do not use serological (antibody) tests as the sole basis to diagnose COVID-19 but instead as information about whether a person may have been exposed.
Be aware that not all marketed serological tests have been evaluated by the FDA. The FDA’s authorized tests, including serological tests, are listed on the Emergency Use Authorization (EUA) page. Tests being offered under a policy outlined in the FDA’s COVID-19 Diagnostic Policy Guidance are listed on our FAQ page. Such tests have not been reviewed by the FDA, unless an EUA has also been submitted and reviewed by FDA."

https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences